Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 9, 2016 - Issue 1
Submit an article Journal homepage
175
Views
12
CrossRef citations to date
0
Altmetric
Perspectives

New drugs and patient-centred end-points in old age: setting the wheels in motion

Arduino A MangoniDiscipline of Clinical Pharmacology, School of Medicine, Flinders University and Flinders Medical Centre, Bedford Park, AustraliaCorrespondence[email protected]
&
Alberto PilottoDepartment of Orthogeriatrics, Rehabilitation and Stabilization, Frailty Area, E.O. Galliera Hospital, National Relevance and High Specialization Hospital, Genova, Italy
Pages 81-89 | Published online: 10 Oct 2015

References

  • Mangoni AA. Geriatric medicine in an aging society: up for a challenge? Front Med (Lausanne). 2014;1:10.
  • Haider SI, Johnell K, Thorslund M, et al. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther. 2007;45(12):643–653.
  • Aparasu RR, Mort JR, Brandt H. Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. Res Social Adm Pharm. 2005;1(3):446–459.
  • Nishtala PS, Salahudeen MS. Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005-2013. Gerontology. 2015;61(3):195–202.
  • Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
  • Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196–1208.
  • Golden AG, Tewary S, Dang S, et al. Care management’s challenges and opportunities to reduce the rapid rehospitalization of frail community-dwelling older adults. Gerontologist. 2010;50(4):451–458.
  • Buckinx F, Rolland Y, Reginster JY, et al. Burden of frailty in the elderly population: perspectives for a public health challenge. Arch Public Health. 2015;73(1):19.
  • Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–762.
  • Prescriptions Dispensed in the Community. Statistics for 1997 to 2007: Leeds (UK): Health & Social Care Information Centre, 2008 July 31. Report No.: IC 2008 10.
  • Mannucci PM, Nobili A, Investigators R. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med. 2014;9(7):723–734.
  • Galvin R, Moriarty F, Cousins G, et al. Prevalence of potentially inappropriate prescribing and prescribing omissions in older Irish adults: findings from The Irish LongituDinal Study on Ageing study (TILDA). Eur J Clin Pharmacol. 2014;70(5):599–606.
  • Kuijpers MA, van Marum RJ, Egberts AC, et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65(1):130–133.
  • Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121–126.
  • Popa MA, Wallace KJ, Brunello A, et al. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014;5(3):307–314.
  • Greene M, Steinman MA, McNicholl IR, et al. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447–453.
  • Herr M, Robine JM, Pinot J, et al. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf. 2015;24(6):637–646.
  • Gomez C, Vega-Quiroga S, Bermejo-Pareja F, et al. Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). Gerontology. 2015;61(4):301–309.
  • Sganga F, Landi F, Ruggiero C, et al. Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study. Geriatr Gerontol Int. 2015;15(2):141–146.
  • Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–995.

* Key study on the cut-offs and adverse effects of polypharmacy in the older population

  • Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521–528.
  • Mangoni AA. Predicting and detecting adverse drug reactions in old age: challenges and opportunities. Expert Opin Drug Metab Toxicol. 2012;8(5):527–530.
  • Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096–1099.
  • Mitrou P, Raptis SA, Dimitriadis G. Thyroid disease in older people. Maturitas. 2011;70(1):5–9.
  • Jackson SH, Jansen PA, Mangoni AA. Off-label prescribing in older patients. Drugs Aging. 2012;29(6):427–434.
  • Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209–220.
  • Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med. 2009;122(12):1142-9 e1-2.
  • Gokula M, Holmes HM. Tools to reduce polypharmacy. Clin Geriatr Med. 2012;28(2):323–341.
  • Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453–1459.
  • Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014;10:CD008165.
  • Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.

* Comprehensive reviews of the available evidence on age-related changes in pharmacokinetics and pharmacodynamics

* Comprehensive reviews of the available evidence on age-related changes in pharmacokinetics and pharmacodynamics

  • Mangoni AA, Jansen PA, Jackson SH. Under-representation of older adults in pharmacokinetic and pharmacodynamic studies: a solvable problem? Expert Rev Clin Pharmacol. 2013;6(1):35–39.
  • Johnston C, Hilmer SN, McLachlan AJ, et al. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014;70(5):549–555.
  • Wynne HA, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing. 1990;19(6):419–424.
  • Williams FM, Wynne H, Woodhouse KW, et al. Plasma aspirin esterase: the influence of old age and frailty. Age Ageing. 1989;18(1):39–42.
  • Mitchell SJ, Kane AE, Hilmer SN. Age-related changes in the hepatic pharmacology and toxicology of paracetamol. Curr Gerontol Geriatr Res. 2011;2011:624156.
  • He X, Clarke SJ, McLachlan AJ. Clinical pharmacology of chemotherapy agents in older people with cancer. Curr Gerontol Geriatr Res. 2011;2011:628670.
  • Clegg A, Relton C, Young J, et al. Improving recruitment of older people to clinical trials: use of the cohort multiple randomised controlled trial design. Age Ageing. 2015;44(4):547–550.
  • Herrera AP, Snipes SA, King DW, et al. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(Suppl 1):S105–12.
  • Polasek TM, Patel F, Jensen BP, et al. Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol. 2013;75(4):1019–1028.
  • Koyanagi T, Nakanishi Y, Murayama N, et al. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. Xenobiotica. 2015;45(4):312–321.
  • Huizer-Pajkos A, Kane AE, Howlett SE, et al. Adverse geriatric outcomes secondary to polypharmacy in a mouse model: the influence of aging. J Gerontol A Biol Sci Med Sci. 2015; in press.
  • Strougo A, Yassen A, Krauwinkel W, et al. A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions. Drug Metab Dispos. 2011;39(7):1278–1287.
  • Rowland Yeo K, Aarabi M, Jamei M, et al. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4(2):261–274.
  • Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
  • Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
  • Callisaya ML, Sharman JE, Close J, et al. Greater daily defined dose of antihypertensive medication increases the risk of falls in older people–a population-based study. J Am Geriatr Soc. 2014;62(8):1527–1533.
  • Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174(4):588–595.
  • Scuffham P, Chaplin S, Legood R. Incidence and costs of unintentional falls in older people in the United Kingdom. J Epidemiol Community Health. 2003;57(9):740–744.
  • Stel VS, Smit JH, Pluijm SM, et al. Consequences of falling in older men and women and risk factors for health service use and functional decline. Age Ageing. 2004;33(1):58–65.
  • Mossello E, Pieraccioli M, Nesti N, et al. Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs. JAMA Intern Med. 2015;175(4):578–585.
  • Abbatecola AM, Bo M, Barbagallo M, et al. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study. J Am Med Dir Assoc. 2015;16(4):349 e7–12.
  • Pilotto A, Noale M, Maggi S, et al. Hypoglycemia is independently associated with multidimensional impairment in elderly diabetic patients. Biomed Res Int. 2014;2014:906103.
  • Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174(7):1116–1124.
  • Majumdar SR, Hemmelgarn BR, Lin M, et al. Hypoglycemia associated with hospitalization and adverse events in older people: population-based cohort study. Diabetes Care. 2013;36(11):3585–3590.
  • Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834.

* Position paper on the rationale for de-prescribing and possible de-prescribing protocols

  • Frank C, Weir E. Deprescribing for older patients. CMAJ. 2014;186(18):1369–1376.
  • Reeve E, Shakib S, Hendrix I, et al. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738–747.
  • Fried TR, McGraw S, Agostini JV, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making. J Am Geriatr Soc. 2008;56(10):1839–1844.
  • Tinetti ME, McAvay GJ, Chang SS, et al. Contribution of multiple chronic conditions to universal health outcomes. J Am Geriatr Soc. 2011;59(9):1686–1691.

* Paper on the identification of non-traditional universal, patient-centered, end-points in older patients

  • Caillet P, Laurent M, Bastuji-Garin S, et al. Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment. Clin Interv Aging. 2014;9:1645–1660.
  • Stuck AE, Siu AL, Wieland GD, et al. Comprehensive Geriatric Assessment: a meta-analysis of controlled trials. Lancet. 1993;342(8878):1032–1036.
  • Bachmann S, Finger C, Huss A, et al. Inpatient rehabilitation specifically designed for geriatric patients: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;340:c1718.
  • Ellis G, Whitehead MA, Robinson D, et al. Comprehensive Geriatric Assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ. 2011;343:d6553.
  • Pilotto A, Ferrucci L, Franceschi M, et al. Development and validation of a multidimensional prognostic index for one-year mortality from Comprehensive Geriatric Assessment in hospitalized older patients. Rejuvenation Res. 2008;11(1):151–161.

* First paper describing the development and validation of the Multidimensional Prognostic Index in older patients

  • Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–919.
  • Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–186.
  • Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975;23(10):433–441.
  • Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15(2):116–122.
  • Bliss MR, McLaren R, Exton-Smith AN. Mattresses for preventing pressure sores in geriatric patients. Mon Bull Minist Health Public Health Lab Serv. 1966;25:238–268.
  • Conwell Y, Forbes NT, Cox C, et al. Validation of a measure of physical illness burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc. 1993;41(1):38–41.
  • Pilotto A, Sancarlo D, Panza F, et al. The Multidimensional Prognostic Index (MPI), based on a Comprehensive Geriatric Assessment predicts short- and long-term mortality in hospitalized older patients with dementia. J Alzheimers Dis. 2009;18(1):191–199.
  • Pilotto A, Addante F, Franceschi M, et al. Multidimensional prognostic index based on a Comprehensive Geriatric Assessment predicts short-term mortality in older patients with heart failure. Circ Heart Fail. 2010;3(1):14–20.
  • Sancarlo D, D’Onofrio G, Franceschi M, et al. Validation of a modified-multidimensional prognostic index (m-MPI) including the mini nutritional assessment short-form (MNA-SF) for the prediction of one-year mortality in hospitalized elderly patients. J Nutr Health Aging. 2011;15(3):169–173.
  • Sancarlo D, Pilotto A, Panza F, et al. A Multidimensional Prognostic Index (MPI) based on a Comprehensive Geriatric Assessment predicts short- and long-term all-cause mortality in older hospitalized patients with transient ischemic attack. J Neurol. 2012;259(4):670–678.
  • Pilotto A, Sancarlo D, Aucella F, et al. Addition of the multidimensional prognostic index to the estimated glomerular filtration rate improves prediction of long-term all-cause mortality in older patients with chronic kidney disease. Rejuvenation Res. 2012;15(1):82–88.
  • Gallucci M, Battistella G, Bergamelli C, et al. Multidimensional prognostic index in a cognitive impairment outpatient setting: mortality and hospitalizations. The Treviso Dementia (TREDEM) study. J Alzheimers Dis. 2014;42(4):1461–1468.
  • Volpato S, Bazzano S, Fontana A, et al. Multidimensional prognostic index predicts mortality and length of stay during hospitalization in the older patients: a multicenter prospective study. J Gerontol A Biol Sci Med Sci. 2015;70(3):325–331.
  • Giantin V, Valentini E, Iasevoli M, et al. Does the Multidimensional Prognostic Index (MPI), based on a Comprehensive Geriatric Assessment (CGA), predict mortality in cancer patients? Results of a prospective observational trial. J Geriatr Oncol. 2013;4(3):208–217.
  • Pilotto A, Rengo F, Marchionni N, et al. Comparing the prognostic accuracy for all-cause mortality of frailty instruments: a multicentre 1-year follow-up in hospitalized older patients. PLoS One. 2012;7(1):e29090.
  • D’Onofrio G, Sancarlo D, Addante F, et al. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2015;30(9):965–975.

* Potential applications of the Multidimensional Prognostic Index as a patient-centered outcome in pharmacological interventions

  • Pilotto A, D’Onofrio G, Panza F, et al. Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index. J Clin Psychopharmacol. 2012;32(5):726–729.

* Potential applications of the Multidimensional Prognostic Index as a patient-centered outcome in pharmacological interventions

  • Aronow WS. Blood pressure goals and targets in the elderly. Curr Treat Options Cardiovasc Med. 2015;17(7):394.
  • Bangalore S, Gong Y, Cooper-DeHoff RM, et al. 2014 eighth joint national committee panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol. 2014;64(8):784–793.
  • James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
  • Mancia G, Fagard R, Narkiewicz K, et al. Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens. 2014;32(8):1551–1552.
  • Grundy SM Cholesterol management in older persons. Am J Med. 2014;127(12):1140–1141.
  • Stone NJ, Blum CB Primary risk prevention in the elderly: use clinician-patient discussions, not automatic statin prescribing. Am J Med. 2015;128(8):804–806.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.